Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ApnimedAPMD +5.99%8 Gross Margin % is 89.98% as of Jun. 2026, which is 28% above its 10-year median of 70.28. GuruFocus rates APMD with a GF Score™ of 8/100. Among 736 Biotechnology companies, Apnimed ranks better than 74.46% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Apnimed's Gross Profit for the
three
months ended in Jun. 2026 was $10.87 Mil. Apnimed's Revenue for the
three
months ended in Jun. 2026 was $12.08 Mil. Therefore, Apnimed's Gross Margin % for the quarter that ended in Jun. 2026 was 89.98%.
The historical rank and industry rank for Apnimed's Gross Margin % or its related term are showing as below:
APMD'
s Gross Margin % Range Over the Past 10 Years
Min: 57.95 Med: 70.28 Max: 82.6
Current: 82.6
During the past 2 years, the highestGross Margin % of Apnimed was 82.60%. The lowest was 57.95%. And the median was 70.28%.
APMD's Gross Margin % is ranked better than 74.46% of 736
companies
in the Biotechnology industry
Industry Median: 60.885
vs APMD: 82.60
Apnimed had a gross margin of 89.98% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Apnimed was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Apnimed had a gross margin of 89.98% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Apnimed Gross Margin % Related Terms
Apnimed Gross Margin % Historical Data
* Premium members only.
The historical data trend for Apnimed's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apnimed Gross Margin % Chart
Apnimed Annual Data
Trend
Dec24
Dec25
Gross Margin %
57.95
82.60
Apnimed Quarterly Data
Mar25
Jun25
Mar26
Jun26
Gross Margin %
57.94
89.92
97.45
89.98
APMD vs SANA, CRVS, ODTX: Gross Margin % Comparison
For the Biotechnology subindustry, Apnimed's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apnimed Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apnimed's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Apnimed's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Apnimed (APMD) has a Gross Margin % of 89.98% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Apnimed and its competitors. This is 28% above median its historical median of 70.28. Over the past decade, Apnimed's Gross Margin % has ranged from 57.95 to 82.60. According to the industry distribution chart, Apnimed ranks #188 out of 736 companies in the Biotechnology industry, placing it in the top 25.5%.
Is Apnimed's Gross Margin % too high?
Apnimed's current Gross Margin % of 89.98% is 28% above median its 10-year median of 70.28. Over the past 10 years, this metric has ranged from a low of 57.95 to a high of 82.60. The Biotechnology industry median Gross Margin % is 60.89. Apnimed's value of 89.98% is 47.8% above this industry median. Based on the distribution chart, Apnimed ranks #188 out of 736 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Apnimed has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Apnimed's Gross Margin % compare to SANA and CRVS?
According to the Biotechnology industry distribution chart, Apnimed ranks #188 out of 736 companies for Gross Margin %. This puts Apnimed in the upper half of its industry. The industry median Gross Margin % is 60.89. Apnimed's value of 89.98% is 47.8% above this benchmark. Historically, Apnimed's own Gross Margin % has ranged from 57.95 to 82.60 over the past decade. While the company's 10-year median is 70.28 vs. the industry median of 60.89, Apnimed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.89, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apnimed's current Gross Margin % of 89.98% is 47.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Apnimed and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apnimed's current Gross Margin % is 89.98%, which is 28% above median its own 10-year median of 70.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apnimed stock overvalued right now?
Apnimed (APMD) has a current Gross Margin % of 89.98%. The current Gross Margin % is 89.98%, which is 28% above median its 10-year median of 70.28 and 47.8% above the Biotechnology industry median of 60.89. Apnimed's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Apnimed (APMD), the current Gross Margin % is 89.98% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score
Get the complete analysis for APMD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APMD has been successfully added to your 
